Skip to main content

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer

Publication ,  Journal Article
Garst, J
Published in: Therapeutics and Clinical Risk Management
December 1, 2007

The topoisomerase I inhibitor topotecan is the only single-agent therapy approved for the treatment of recurrent small cell lung cancer (SCLC). Many patients with recurrent SCLC may be predisposed to treatment-related adverse events because of the presence of comorbidities such as advanced age, renal impairment, or extensive prior therapy. In this setting, disease stabilization is considered a treatment benefit, and quality-of-life effects and toxicity profiles of treatments should be considered. The approved regimen of topotecan 1.5 mg/m2 on days 1 to 5 of a 21-day cycle is active and has generally mild nonhematologic toxicity and a well-established hematologic toxicity profile characterized by reversible, manageable, and noncumulative neutropenia. Alternative dosing and treatment schedules may lower the incidence of hematologic toxicities while maintaining antitumor efficacy in this patient population. Therefore, topotecan may provide physicians with an effective and versatile therapeutic option for the treatment of patients with relapsed SCLCT. © 2007 Dove Medical Press Limited. All rights reserved.

Duke Scholars

Published In

Therapeutics and Clinical Risk Management

ISSN

1176-6336

Publication Date

December 1, 2007

Volume

3

Issue

6

Start / End Page

1087 / 1095

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Garst, J. (2007). Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. Therapeutics and Clinical Risk Management, 3(6), 1087–1095.
Garst, J. “Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.” Therapeutics and Clinical Risk Management 3, no. 6 (December 1, 2007): 1087–95.
Garst J. Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. Therapeutics and Clinical Risk Management. 2007 Dec 1;3(6):1087–95.
Garst, J. “Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.” Therapeutics and Clinical Risk Management, vol. 3, no. 6, Dec. 2007, pp. 1087–95.
Garst J. Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. Therapeutics and Clinical Risk Management. 2007 Dec 1;3(6):1087–1095.

Published In

Therapeutics and Clinical Risk Management

ISSN

1176-6336

Publication Date

December 1, 2007

Volume

3

Issue

6

Start / End Page

1087 / 1095

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services